Selling, General, and Administrative Costs: Zoetis Inc. vs Protagonist Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Protagonist Therapeutics, Inc. from 2014 to 2023.

Zoetis Inc.: A Steady Climb

Zoetis Inc., a leader in animal health, has consistently invested in its SG&A expenses, reflecting a strategic focus on growth and market expansion. Over the past decade, their expenses have increased by approximately 31%, reaching a peak in 2023. This steady climb underscores Zoetis's commitment to maintaining its market position.

Protagonist Therapeutics, Inc.: Rapid Growth

In contrast, Protagonist Therapeutics, Inc., a smaller biotech firm, has seen a dramatic rise in SG&A expenses, surging by over 1,700% since 2014. This rapid growth highlights their aggressive investment in research and development, aiming to carve out a niche in the competitive biotech sector.